IL142803A0 - Pharmaceutical compositions containing r-tofisopam - Google Patents

Pharmaceutical compositions containing r-tofisopam

Info

Publication number
IL142803A0
IL142803A0 IL14280399A IL14280399A IL142803A0 IL 142803 A0 IL142803 A0 IL 142803A0 IL 14280399 A IL14280399 A IL 14280399A IL 14280399 A IL14280399 A IL 14280399A IL 142803 A0 IL142803 A0 IL 142803A0
Authority
IL
Israel
Prior art keywords
tofisopam
pharmaceutical compositions
compositions containing
anxiety
enantiomer
Prior art date
Application number
IL14280399A
Other languages
English (en)
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of IL142803A0 publication Critical patent/IL142803A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14280399A 1998-10-27 1999-10-27 Pharmaceutical compositions containing r-tofisopam IL142803A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Publications (1)

Publication Number Publication Date
IL142803A0 true IL142803A0 (en) 2002-03-10

Family

ID=22307874

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14280399A IL142803A0 (en) 1998-10-27 1999-10-27 Pharmaceutical compositions containing r-tofisopam
IL142803A IL142803A (en) 1998-10-27 2001-04-25 Pharmaceutical compositions containing r-tofisopam

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142803A IL142803A (en) 1998-10-27 2001-04-25 Pharmaceutical compositions containing r-tofisopam

Country Status (16)

Country Link
EP (1) EP1124556B1 (enExample)
JP (2) JP2003522112A (enExample)
AT (1) ATE269705T1 (enExample)
AU (1) AU1451900A (enExample)
BR (1) BR9914899A (enExample)
CA (1) CA2348281A1 (enExample)
DE (1) DE69918322T2 (enExample)
DK (1) DK1124556T3 (enExample)
ES (1) ES2224751T3 (enExample)
GB (1) GB2367748A (enExample)
HK (2) HK1040908B (enExample)
IL (2) IL142803A0 (enExample)
NZ (1) NZ511744A (enExample)
PT (1) PT1124556E (enExample)
WO (1) WO2000024400A1 (enExample)
ZA (1) ZA200103376B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
US6864251B2 (en) 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
JP2006514084A (ja) * 2002-12-03 2006-04-27 ヴェラ ファーマスーティカルズ インコーポレイテッド 1−(3−ヒドロキシ−4−メトキシフェニル)−4−メチル−5−エチル−7,8−ジメトキシ−5h−2,3−ベンゾジアゼピンの製薬組成物及びその用途
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
AU2003293405A1 (en) 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
EP1689408A4 (en) * 2003-12-03 2010-03-03 Vela Acquisition Corp TREATMENT OF INFLAMMATORY DISORDERS OF EPITHELIUM USING LOW DOSE 2,3-BENZODIAZEPINES
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Also Published As

Publication number Publication date
EP1124556A1 (en) 2001-08-22
JP2007211028A (ja) 2007-08-23
WO2000024400A1 (en) 2000-05-04
IL142803A (en) 2006-10-05
CA2348281A1 (en) 2000-05-04
ZA200103376B (en) 2003-09-09
GB2367748A8 (en) 2002-12-19
DE69918322T2 (de) 2005-09-15
BR9914899A (pt) 2001-07-17
HK1040908A1 (en) 2002-06-28
AU1451900A (en) 2000-05-15
ES2224751T3 (es) 2005-03-01
HK1040908B (en) 2005-04-22
GB2367748A (en) 2002-04-17
NZ511744A (en) 2004-04-30
DK1124556T3 (da) 2004-10-11
JP2003522112A (ja) 2003-07-22
HK1046500A1 (zh) 2003-01-17
DE69918322D1 (de) 2004-07-29
PT1124556E (pt) 2004-10-29
EP1124556B1 (en) 2004-06-23
ATE269705T1 (de) 2004-07-15
GB0111739D0 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
SI0725779T1 (enExample)
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
GB2349570B (en) Compositions for treatment of disorders of the oesophagus associated with reflux
BG104561A (en) Aryl fused azapolycyclic compounds
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
SG148846A1 (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimeræs and related neurodegenerative disorders
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
IL138129A (en) Composition for therapy of estrogen-associated disorders
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
DK0687176T3 (da) Anvendelse af riluzol til behandling af AIDS-relaterede nervesygdomme
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
MXPA02012626A (es) Bis-arilsufonas.
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
BG105256A (en) Muscarinic agonists and antagonists
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
MY133474A (en) Aryl fused azapolycyclic compounds
GB9907571D0 (en) Compounds
HUP0101748A3 (en) Use of reboxetine for producing pharmaceutical compositions suitable for treating nervous disorders
MY138319A (en) 1,5-benzodiazepine derivatives
AP2000001963A0 (en) Paroxetine ascorbate.
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
EP0928792A3 (en) Bicyclic(3.1.0)hexanes and related compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed